PerkinElmer Inc. bought GE Healthcare‘s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay reagents and Cytostar-T plate product lines for an undisclosed amount.

The Waltham, Mass.-based device and diagnostics giant said the catalog radiochemicals are used in binding assays to screen potential drug candidates. The SPA bead-based light-emitting assay and Cytostar-T plate technologies enable the automation of high throughput screening processes for drug discovery.

PerkinElmer claims the purchase gives it the world’s largest portfolio of radiolabeled compounds, adding that it plans to continue expanding the offering.

The company posted second-quarter net income of $21.5 million on sales of $434.6 million, down 9.3 percent and 14 percent, respectively, compared with the same period last year.